Summary
- CNS Pharmaceuticals has filed to raise $9.6 million from an IPO.
- The firm is developing Berubicin, a compound for the treatment of brain tumors.
- While I wish CNSP well, the IPO has no investor support and the firm is still very early stage.
- Looking for a community to discuss ideas with? IPO Edge features a chat room of like-minded investors sharing investing ideas and strategies. Start your free trial today »
Quick Take
CNS Pharmaceuticals (CNSP) has filed to raise gross proceeds of $9.6 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing therapeutics for primary and metastatic brain and central nervous system tumors.
CNSP is a very early-stage firm with few resources and no discernible investor support for the IPO.
